Developing cannabinoid treatments for migraines
Optimization of Cannabinoids for Development as FDA-Approved Migraine Therapeutics
['FUNDING_SBIR_2'] · SCHEDULE 1 THERAPEUTICS, INC. · NIH-10822898
This study is testing a new treatment called S1-220, which combines CBD and THC, to help people with migraines find better relief, and it's aimed at getting approval from the FDA after promising early results.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SCHEDULE 1 THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-10822898 on ClinicalTrials.gov |
What this research studies
This research focuses on creating optimized cannabinoid therapeutics specifically for treating migraines, which affect a significant portion of the population. The team aims to gain FDA approval for a new treatment called S1-220, a combination of CBD and THC, which has shown promise in preclinical trials without adverse effects. By utilizing a novel approach to drug design, the research seeks to provide effective relief for patients who currently struggle with inadequate migraine treatments. The goal is to initiate a phase 1 clinical trial to further evaluate the safety and efficacy of this new therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who experience chronic migraines and have not found relief with existing treatments.
Not a fit: Patients who do not suffer from migraines or have contraindications to cannabinoid therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from migraines.
How similar studies have performed: Previous studies have indicated potential efficacy of cannabinoids in treating migraines, but this approach aims to optimize the treatment through a novel drug design.
Where this research is happening
CHICAGO, UNITED STATES
- SCHEDULE 1 THERAPEUTICS, INC. — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PAPPAS, GEORGE — SCHEDULE 1 THERAPEUTICS, INC.
- Study coordinator: PAPPAS, GEORGE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: CNS Diseases, CNS disorder